Paolo Tarantino: Phase 1 trial of the MMAF-based, HER2-targeting ADC FS-1502 published in Nature Communications

Paolo Tarantino shared on X/Twitter:

“Phase 1 trial of the MMAF-based, HER2-targeting ADC FS-1502 published in Nature Communications. Among 67 patients with HER2+ MBC receiving the 2.3 mg/kg dose, ORR was 53.7%, mPFS 15.5 months. Main adverse effects: liver toxicity, keratitis, hypokalemia. Phase 3 trial ongoing vs. T-DM1.”

Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer.

Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.

With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.